Thinking about treatment with IMBRUVICA®?
Sign up today to receive the latest information and helpful resources.
In a clinical trial of 269 people, 8% of CLL patients on IMBRUVICA® (ibrutinib) died versus 16% taking a chemotherapy (chlorambucil), after 28 months of follow-up.1*
Here’s to more time together and the opportunity to keep doing what you love.
Here’s to saving on IMBRUVICA®
You may pay as little as $0 per prescription with the IMBRUVICA® Copay Card. Subject to eligibility; restrictions apply.†
Enroll Now
Receive one-on-one support plus financial and educational resources to help start and stay on track with IMBRUVICA®‡
Explore Support Options
IMBRUVICA® for CLL
Questions to ask your doctor about CLL and IMBRUVICA®
Get More InformationAbout IMBRUVICA® for CLL
Learn from a patient
Real stories from CLL patients about their experience with IMBRUVICA®
View PatientVideos Here
In one clinical trial of 269 people aged 65 and older with CLL or SLL who had not been treated before, people who took IMBRUVICA® had a 56% lower risk of death compared to those taking a chemotherapy (chlorambucil). With a median follow-up of approximately 28 months, 8% of IMBRUVICA® patients died compared to 16% taking a chemotherapy.
Starting treatment is an important time in your journey with CLL/SLL. This website will help you learn more about your condition and how IMBRUVICA® can help.
IMBRUVICA® works differently from chemotherapy. This once-daily, oral medication blocks a protein in B cells called Bruton's tyrosine kinase, or BTK. For more complete information on how IMBRUVICA® works and the possible side effects, go to the How Does IMBRUVICA® Work? section.1
IMBRUVICA® is a prescription medicine used to treat adults with:
- Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)
- Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion
It is not known if IMBRUVICA® is safe and effective in children.
From the moment you’re prescribed IMBRUVICA®, IMBRUVICA® By Your Side provides resources and support for getting the help you may need during treatment.
Coverage and Cost
Confirm your coverage and out-of-pocket costs for IMBRUVICA®.
Support Communications
Receive periodic emails with tips and information about treatment.
IMBRUVICA® By Your Side Ambassadors*
Call a By Your Side Ambassador if you have questions about IMBRUVICA®.
†Eligible patients may pay as little as $0 per prescription of IMBRUVICA®. Rules and maximum limits apply. Patients currently using the IMBRUVICA® Copay Card are not eligible for retroactive billing or reimbursement of previous copays. The IMBRUVICA® Copay Card is available to patients with commercial prescription coverage for IMBRUVICA® who meet eligibility criteria. The IMBRUVICA® Copay Card cannot be used by patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs, including Medicare Part D, Medicare Advantage Plan, Medicaid, Medigap, VA, DOD, and TRICARE, or where prohibited by law or the patient’s health insurance provider. The IMBRUVICA® Copay program may be updated or discontinued at any time without notice.
‡IMBRUVICA® By Your Side patient support program is not intended to provide medical advice, replace prescribed treatment plans, or provide treatment or case management services. Patients are advised to talk to their healthcare provider and treatment team about any medical decisions and concerns they may have. By Your Side Ambassadors are provided by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie Company, and do not work under the direction of your healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.
References: 1. IMBRUVICA® (ibrutinib) Prescribing Information. 2. National Institutes of Health. BTK gene. Accessed June 6, 2023. https://medlineplus.gov/genetics/gene/btk/